Purpose: Transrectal ultrasound images are routinely acquired for low dose rate (LDR) prostate brachytherapy dosimetric preplanning (pTRUS), although diagnostic multiparametric magnetic resonance imaging (mpMRI) may serve this purpose as well. We compared the predictive abilities of TRUS vs MRI relative to intraoperative TRUS (iTRUS) to assess the role of mpMRI in brachytherapy preplanning.
planning and delivery can serve to establish mpMRI as the standard of care in LDR prostate brachytherapy planning. Group study RTOG 98-05. In this multicenter phase II trial, patients with localized prostate adenocarcinoma (PCa) underwent a preplanning TRUS (pTRUS) volume study alone to plan and guide transperineal low dose rate (LDR) permanent seed implant procedures. This study showed good biochemical control rates, favorable toxicity profiles, and overall survival comparable to other brachytherapy, external beam, and surgical series. 1, 2 In addition to preplan imaging which is critical for determining the correct seed quantity and activity, intraoperative planning using TRUS (iTRUS) has been shown to provide important, accurate volume and mapping information to enhance seed placement and limit toxicity to nearby organs. 3, 4 Application of magnetic resonance imaging (MRI) for identification and diagnosis of PCa dates back over 30 years. 5 While older iterations of prostate MRI technique lacked sensitivity and specificity (particularly for early-stage tumors), 6 MRI performance has rapidly improved as higher resolution imaging has evolved over the past decade and is expected to further improve with sequence optimizations and other 3D resolution applications. In this setting, MRI has emerged as a useful tool for assessing preoperative staging of PCa.
Most recently, multiparametric MRI (mpMRI) sequences (T2-weighted, diffusion-weighted, DCE, MR spectroscopic imaging) have been shown to add important functional data to standard cross-sectional findings, motivating the European Society of Urogenital Radiology (ESUR) to publish clinical guidelines for its use in PCa detection and staging. 7, 8 Beyond its diagnostic utility, strong evidence is evolving for the role of mpMRI and image fusion as a useful aid in the treatment planning of prostate cancer. 9 mpMRI in addition to TRUS may enable more precise targeting of high-risk intraprostatic regions without unnecessarily increasing dose to surrounding structures, thereby improving local control. 10, 11 In this new era of pretreatment MRI volume studies, the standard pTRUS, which causes a fair amount of patient discomfort and requires additional time and staff, may prove to be redundant. Concern, however, has been raised over the consistency between prostate volumes measured on TRUS compared to those from MRI.
While some reports have demonstrated a tendency of preplan MRI (as well as CT) to overestimate prostate volume compared with ultrasound, 12, 13 others found MRI to underestimate gland size relative to TRUS. 14, 15 In order to further study the ability of MRI-based preplanning to reliably predict the intraoperative TRUS-based parameters for LDR brachytherapy, we prospectively performed a series of dosimetric preplans using both pTRUs and mpMRI during our transition from pTRUS-to mpMRI-based planning. Specifically, we compared both pTRUS-only-planned studies and MRI-planned studies with a final iTRUS plan to determine the frequency and magnitude of dosimetric changes. The impact of volumetric variation was quantified through changes in the total seed activity necessary and, therefore, in the number of seeds required. The burden of MRI/TRUS fusion was assessed through changes in total procedure and anesthesia time.
| METHODS
Institutional Review Board (IRB) approval was obtained for a retrospective review of our prospectively planned patients with localized prostate cancer treated who underwent LDR permanent seed implantation at our institution from September 5, 2012 to September 6, 2013. Thirty-two patients underwent LDR permanent seed implantation during the study period, all of whom received a pTRUS volume study from which the quantity of seeds and total activity were determined. During the transition to MRI-based preplanning, an additional mpMRI was performed on 14 of these patients (43.7%).
All preplan imaging was acquired in the department of radiation oncology, overseen by a single radiation oncologist who specializes in brachytherapy. The same radiation oncologist, assisted by a single certified medical physicist, performed the brachytherapy preplanning, iTRUS planning, and seed implantation.
Pretreatment volume studies were acquired 2-3 weeks prior to the brachytherapy procedure. pTRUS was performed using a standard rectal ultrasound probe (BK Medical, Model: Flex Focus 8848) mounted on a manual stepper unit and template, synchronized with MIM symphony software/planning system (MIM, Beachwood, OH).
Patients were placed in the dorsal lithotomy position and pTRUS images were acquired at 5 mm spacing. These cross-sectional images were used to delineate the required contours and generate a pTRUS-based dosimetric plan. For treatment planning with MRI, multiparametric sequences (T1, T2, dynamic contrast-enhanced series (DCE), diffusion-weighted imaging (DWI)) were acquired through the pelvis with patients in the supine position, and the T2 sequence was used to derive the prostate volume and the number of brachytherapy seeds, from which total seed activity was determined. Multiparametric sequences were used to radiographically identify regions highly suspicious for tumor foci based on the Prostate Imaging
Reporting and Data System (PIRADS) scoring system. 8 Typically, a combination of the T2-weighted series then verified on DCE and DWI were referenced to identify foci of disease. imaging methods for agreement with the iTRUS treatment. The difference of two coefficients was examined by Fisher's Z transformation test. A P-value of < 5% was considered statistically significant.
| RESULTS
Patient demographics between pTRUS alone and pTRUS/mpMRI groups were comparable (Table 1) . 88.9% and 78.6% of the pTRUS and mpMRI groups, respectively, had a pretreatment PSA < 10 ng/ mL, 77.8%, and 71.4% had Gleason scores 6 or 7 and 88.9% and 85.7% had a clinical stage of T1c.
Both pTRUS-based and MRI-based preplans accurately and con- respectively. When stratifying for HT use, the difference in volume for the preplanning modalities was nonsignificant (P = 0.35).
In 11 (79%) cases, for which an mpMRI was obtained, a region highly suspicious for focal disease was detected and noted on final radiology read as a PIRADS 4 or 5. None of these biopsy-provendominant tumor foci were retroactively seen on the corresponding pTRUS series. In all cases, the lesions were contoured in the mpMRIpreplans as well as in the intraoperative plans and specifically targeted with dose escalation to 200% of prescription (Fig. 2) . This was accomplished through intraoperative MRI/TRUS fusion and real-time planning. All of these index lesions were located, at least in part, in the peripheral zone of the gland, and mpMRI allowed confident exclusion of any concern for extraprostatic extension. When reviewed retrospectively, as above, this distinction was not apparent on TRUS imaging, nor was accurate delineation of zonal anatomy.
There was no significant difference observed in each of the modality's ability to accurately predict the number of seeds that would be required for the brachytherapy implant (Table 2) . Mean differences between iTRUS vs pTRUS and iTRUS vs MRI were 7 ± 4 (P = 0.92) and 5 ± 4 (P = 0.31), respectively, with correlation coefficient r values of 0.87 and 0.86, respectively (Fig. 3 ). The intersample difference was nonsignificant (P = 0.62). The mean percent differences between iTRUS vs pTRUS and iTRUS vs MRI were 10 ± 5% and 7 ± 7%, respectively. Predictive abilities were comparable as well in those who had received prior HT, with mean differences between iTRUS vs pTRUS and iTRUS vs MRI of 7 ± 4 (P = 0.31) and 3 ± 2 (P = 0.15), respectively. The intersample difference was similarly nonsignificant (P = 0.11). The mean percent differences between iTRUS vs pTRUS and iTRUS vs MRI were 10 ± 4% and 3 ± 2%, respectively. Both imaging modalities yielded similar predictions of required intraoperative total activity, with mean differences of 7 ± 8 mCi (P = 0.42) and 7 ± 8 mCi (P = 0.68) for iTRUS vs pTRUS and iTRUS vs MRI, respectively, the difference between which was not significant (P = 0.94). incurs lower OR suite costs. 27 Importantly, our data demonstrate that the addition of intraoperative mpMRI/TRUS fusion and planning did not significantly increase total OR time. In addition, studies have demonstrated correlation between longer total anesthesia time and increased risk to the patient. 28 We demonstrated no difference in mean anesthesia time between pTRUS-alone-planned cases and mpMRI-planned cases.
The application of MRI in brachytherapy treatment planning has become more routine in treatment planning of pelvic malignancies, both in the realm of gynecologic 29 and genitourinary tumors. 35, 36 Of course, these methods of image-guided targeted biopsy to inform targeted treatment are imperfect and require continued investigation and improvement, an area that we continue to actively investigate. It has become our institutional practice to obtain a diagnostic/planning mpMRI prior to all prostate radiation treatment, including brachytherapy, photon and proton external beam radiation, stereotactic radiotherapy and partial prostate treatment on protocol.
As illustrated in this experience ( 
